Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Catechol-O-methyltransferase inhibition improves levodopa-associated strength increase in patients with Parkinson disease.

Müller T, Kolf K, Ander L, Woitalla D, Muhlack S.

Clin Neuropharmacol. 2008 May-Jun;31(3):134-40. doi: 10.1097/WNF.0b013e31811510ed.

PMID:
18520980
2.
3.

Pharmacokinetic behaviour of levodopa and 3-O-methyldopa after repeat administration of levodopa/carbidopa with and without entacapone in patients with Parkinson's disease.

Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Goetze O, Woitalla D.

J Neural Transm (Vienna). 2006 Oct;113(10):1441-8.

PMID:
16604302
4.

Relationship between 3-O-methyldopa and the clinical effects of entacapone in advanced Parkinson's disease.

Ishihara A, Miyachi T, Nakamura T, Ohtsuki T, Kimura Y, Kihira K, Yamawaki T, Matsumoto M.

Hiroshima J Med Sci. 2011 Sep;60(3):57-62.

PMID:
22053701
5.

Inhibition of catechol-O-methyltransferase contributes to more stable levodopa plasma levels.

Müller T, Erdmann C, Muhlack S, Bremen D, Przuntek H, Woitalla D.

Mov Disord. 2006 Mar;21(3):332-6.

PMID:
16211593
6.

The COMT Val158Met polymorphism affects the response to entacapone in Parkinson's disease: a randomized crossover clinical trial.

Corvol JC, Bonnet C, Charbonnier-Beaupel F, Bonnet AM, Fiévet MH, Bellanger A, Roze E, Meliksetyan G, Ben Djebara M, Hartmann A, Lacomblez L, Vrignaud C, Zahr N, Agid Y, Costentin J, Hulot JS, Vidailhet M.

Ann Neurol. 2011 Jan;69(1):111-8. doi: 10.1002/ana.22155.

PMID:
21280081
8.

Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.

Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.

Clin Neuropharmacol. 2008 Jan-Feb;31(1):2-18. doi: 10.1097/wnf.0b013e3180645cb0.

PMID:
18303486
9.

Simultaneous MAO-B and COMT inhibition in L-Dopa-treated patients with Parkinson's disease.

Lyytinen J, Kaakkola S, Ahtila S, Tuomainen P, Teräväinen H.

Mov Disord. 1997 Jul;12(4):497-505.

PMID:
9251066
10.

Entacapone: a catechol-O-methyltransferase inhibitor for the adjunctive treatment of Parkinson's disease.

Najib J.

Clin Ther. 2001 Jun;23(6):802-32; discussion 771. Review.

PMID:
11440283
11.

Fewer fluctuations, higher maximum concentration and better motor response of levodopa with catechol-O-methyltransferase inhibition.

Muhlack S, Herrmann L, Salmen S, Müller T.

J Neural Transm (Vienna). 2014 Nov;121(11):1357-66. doi: 10.1007/s00702-014-1213-3.

PMID:
24770794
12.

Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease.

Müller T, Woitalla D, Muhlack S.

Naunyn Schmiedebergs Arch Pharmacol. 2011 Jun;383(6):627-33. doi: 10.1007/s00210-011-0629-7.

PMID:
21533995
13.

Peripheral COMT inhibition prevents levodopa associated homocysteine increase.

Müller T, Muhlack S.

J Neural Transm (Vienna). 2009 Oct;116(10):1253-6. doi: 10.1007/s00702-009-0275-0.

PMID:
19657587
14.

The effects of different repeated doses of entacapone on the pharmacokinetics of L-Dopa and on the clinical response to L-Dopa in Parkinson's disease.

Heikkinen H, Nutt JG, LeWitt PA, Koller WC, Gordin A.

Clin Neuropharmacol. 2001 May-Jun;24(3):150-7.

PMID:
11391126
15.
16.

Impact of gastric emptying on levodopa pharmacokinetics in Parkinson disease patients.

Müller T, Erdmann C, Bremen D, Schmidt WE, Muhlack S, Woitalla D, Goetze O.

Clin Neuropharmacol. 2006 Mar-Apr;29(2):61-7.

PMID:
16614536
17.
18.

Entacapone.

Müller T.

Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):983-93. doi: 10.1517/17425255.2010.502167. Review.

PMID:
20572781
19.

The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease.

Piccini P, Brooks DJ, Korpela K, Pavese N, Karlsson M, Gordin A.

J Neurol Neurosurg Psychiatry. 2000 May;68(5):589-94.

20.

Pharmacokinetic-pharmacodynamic interaction between nebicapone and controlled-release levodopa/benserazide: a single-center, Phase I, double-blind, randomized, placebo-controlled, four-way crossover study in healthy subjects.

Nunes T, Machado R, Rocha JF, Fernandes-Lopes C, Costa R, Torrão L, Loureiro AI, Falcão A, Vaz-da-Silva M, Wright L, Almeida L, Soares-da-Silva P.

Clin Ther. 2009 Oct;31(10):2258-71. doi: 10.1016/j.clinthera.2009.10.019.

PMID:
19922897
Items per page

Supplemental Content

Support Center